Rep. Byron Donalds Sells Off Abbott Laboratories (NYSE:ABT) Stock

Representative Byron Donalds (R-Florida) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 4th. The trade occurred in the Representative’s “MORAN WEALTH IRA” account.

Representative Byron Donalds also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Comfort Systems USA (NYSE:FIX) on 12/4/2025.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Brown & Brown (NYSE:BRO) on 10/24/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 10/24/2025.
• Sold $1,001 – $15,000 in shares of Howmet Aerospace (NYSE:HWM) on 10/23/2025.
• Purchased $1,001 – $15,000 in shares of Trade Desk (NASDAQ:TTD) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Chipotle Mexican Grill (NYSE:CMG) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Carnival (NYSE:CCL) on 10/9/2025.
• Purchased $1,001 – $15,000 in shares of Fortinet (NASDAQ:FTNT) on 10/9/2025.

Abbott Laboratories Stock Performance

NYSE ABT opened at $126.21 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a market cap of $219.46 billion, a P/E ratio of 15.82, a P/E/G ratio of 2.10 and a beta of 0.72. The stock has a 50-day moving average of $126.08 and a two-hundred day moving average of $129.47. Abbott Laboratories has a 1-year low of $110.86 and a 1-year high of $141.23.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 EPS for the quarter, meeting the consensus estimate of $1.30. The business had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same quarter last year, the firm posted $1.21 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a $0.63 dividend. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.0%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s dividend payout ratio (DPR) is presently 29.57%.

Analyst Upgrades and Downgrades

Several research firms have commented on ABT. Benchmark assumed coverage on shares of Abbott Laboratories in a research note on Friday, October 10th. They issued a “buy” rating and a $145.00 price target for the company. Daiwa Capital Markets lifted their target price on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a report on Tuesday, October 21st. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Abbott Laboratories in a research report on Monday, December 29th. Finally, Evercore ISI boosted their price objective on Abbott Laboratories from $142.00 to $144.00 and gave the stock an “outperform” rating in a research report on Monday. Two analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $147.47.

Institutional Trading of Abbott Laboratories

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ABT. Carr Financial Group Corp raised its stake in Abbott Laboratories by 2.0% during the 3rd quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock worth $520,000 after acquiring an additional 76 shares in the last quarter. Tortoise Investment Management LLC increased its position in shares of Abbott Laboratories by 10.7% during the second quarter. Tortoise Investment Management LLC now owns 795 shares of the healthcare product maker’s stock worth $108,000 after purchasing an additional 77 shares in the last quarter. Gemmer Asset Management LLC increased its position in shares of Abbott Laboratories by 2.9% during the third quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after purchasing an additional 78 shares in the last quarter. FF Advisors LLC boosted its position in shares of Abbott Laboratories by 4.3% in the 2nd quarter. FF Advisors LLC now owns 1,904 shares of the healthcare product maker’s stock valued at $259,000 after purchasing an additional 79 shares during the period. Finally, Charles Schwab Trust Co grew its stake in Abbott Laboratories by 0.6% during the 2nd quarter. Charles Schwab Trust Co now owns 14,018 shares of the healthcare product maker’s stock worth $1,907,000 after buying an additional 79 shares during the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

About Representative Donalds

Byron Donalds (Republican Party) is a member of the U.S. House, representing Florida’s 19th Congressional District. He assumed office on January 3, 2021. His current term ends on January 3, 2027.

Donalds (Republican Party) is running for re-election to the U.S. House to represent Florida’s 19th Congressional District. He declared candidacy for the 2026 election.

Byron Donalds was born in Brooklyn, New York, and lives in Naples, Florida. Donalds earned a bachelor’s degree in finance and marketing from Florida State University in 2002. His career experience includes working as a commercial credit officer in banking and as a portfolio manager in financial services.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.